Provide solutions to healthcare professionals to save heart failure patients and offer them an active life.
CorWave is a high-growth company incorporated in 2012 by the startup studio MD Start and supported by renowned investors. We raised more than 80 million euros in funding, and the company employs more than 70 people. Since its creation, the company has won numerous awards and competitions.
Invention of wave membrane technology by Jean-Baptiste Drevet, he collaborates with the CNRS and creates AMS R&D
Creation of the company CorWave by the startup studio MD Start and exclusive license agreement with AMS R&D
CorWave joins Agoranov Incubator
€ 3.3M in Series A financing raised from Bpifrance, Seventure and Sofinnova
First presentation at a scientific congress of cardiac surgery
CorWave joins Paris Biotech Santé incubator
Participates in the Worldwide Innovation Challenge, wins phase 1 for the NovaPulse project (Nemo development)
€15.5M in series B financing raised from Novo Seeds, Ysios Capital and existing investors
Participates in the Worldwide Innovation Challenge, wins phase 2 for the NovaPulse project
Receives the Deloitte Technology Fast 50 Biotech Future award
CorWave sets up a 1,300 m² facility near Paris, with laboratories and a pilot production unit
Nominated for “Trophée des Futures Licornes” award
Receives a PSPC grant by BPI for the Calypso project, in partnership with Lille University Hospital and AP-HP-Pitié Salpêtrière Hospital
First patent granted in the US
Performs a successful chronic preclinical study
Selected among KPMG Tech Pulse 40 companies
Receives “Trophée de l’embarqué” award for healthcare category
Receives an EIC Accelerator grant from the European Commission
Selected as a Showcase Company by Medtech Innovator
€35M in series C financing raised from historic investors joined by the EIC Fund and Financière Arbevel
CorWave is part of the French Tech 120 index, a selection of 120 French startups and scaleups with the potential to become global technology leaders
CorWave starts setting up its new manufacturing facility
Second closing of CorWave’s Series C at €61M led by Bpifrance’s SPI fund and bolstered by strategic investors, notably Exor Ventures and Vlerick Group
CorWave is part of the French Tech 120 index, a selection of 120 French startups and scaleups with the potential to become global technology leaders.
This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 954151.
CorWave’s Industrialization program is supported by the Paris region through the call for projects “Relance Industrie”.
CorWave’s R&D program is supported by the French state through the “Programme d’Investissements d’Avenir” (PIA).
Lille University Hospital and the Pitié-Salpêtrière Hospital (AP-HP) are CorWave’s partners within this R&D program.